Current Opinion in HIV and AIDS was launched in 2006. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The fields of HIV and AIDS are divided into 6 sections per year. Each section is assigned Section Editors, leading authorities in the area, who identify the most important topics at that time. Here we are pleased to introduce the Editors for the journal and the Section Editors for this issue.
David A. Cooper
David Cooper AO FAA, Scientia Professor of Medicine at the University of New South Wales, Australia is Director of the National Centre in HIV Epidemiology and Clinical Research, Sydney, Australia. The National Centre is funded by the Commonwealth Department of Health and Ageing to conduct research into the HIV/AIDS epidemic in Australia with the ultimate aim of reducing the burden of the HIV/AIDS epidemic for the affected community.
The major responsibilities of the National Centre are the epidemiology and surveillance of HIV/AIDS in Australia, including research aspects and the coordination and conduct of clinical trials of innovative therapies and vaccines for HIV disease, as well as an active clinical research program with particular emphasis on HIV infection, viral hepatitis and sexually-transmitted infections.
In addition to the National Centre, Professor Cooper is a physician in the Immunology/HIV/Infectious Diseases Clinical Services Unit at St Vincent's Hospital, Sydney, one of the largest inpatient and outpatient services for the treatment of HIV disease in Australia. He is Director of the St Vincent's Hospital Centre for Applied Medical Research. Professor Cooper is an author on over 500 published scientific papers and is on the editorial boards of several international journals.
Internationally, Professor Cooper is recognized as a leading HIV clinician and clinical investigator. He is a past President of the International AIDS Society. He is a Director of HIVNAT, a clinical research and trials collaboration based at the Thai Red Cross AIDS Research Centre at the Chulalongkorn University Hospital in Bangkok, Thailand. He is actively involved in studies of biomedical prevention strategies for HIV infection in the developing world including vaccines and chemoprophylaxis.
Professor Giuseppe Pantaleo was born June 17, 1956 in Bari, Italy. In 1980, he received his degree in medicine with full marks and honors, and in 1983, he obtained the Board in clinical hematology.
His scientific career in the field of immunology began in 1983 working on the development of a limiting dilution cloning system which was critical for the subsequent studies aimed at the phenotypic and functional characterization of circulating T lymphocytes. From 1985 to 1987 he was amongst the pioneers in the delineation of the molecular and biochemical mechanisms involved in signal transduction in human T lymphocytes.
In 1989, Professor Pantaleo joined the Laboratory of Immunoregulation, NIAID, NIH. He was the first to demonstrate the defective clonogenic potential of CD8+ T lymphocytes and the selective defect of HIV-specific cytotoxic T lymphocytes. He then studied the relationship between immune response and viral reservoirs in different anatomic compartments. He demonstrated that lymphoid organs function as a major reservoir for HIV, and that active virus replication occurs in lymphoid organs throughout the course of HIV disease including the prolonged period of clinical latency. These findings have completely changed the clinical and therapeutic management of HIV infection. In the following years, he has continued to provide important contributions to the understanding of the immunopathogenesis of HIV infection. Amongst these it is noteworthy to mention the delineation of the virologic and immunologic events associated with primary HIV infection, and the observation that the proportion of CD8+ T cells involved in antiviral immune response was substantially higher compared to what was previously estimated.
Since 1997 he has pioneered the field of immune-based intervention in HIV infection and he has been part of a European program for the development of a vaccine against HIV-AIDS. Since 2005, he has been leading the Poxvirus T-cell Vaccine Discovery consortium, an international program to develop an HIV vaccine supported by the Bill and Melinda Gates Foundation.
Professor Pantaleo is author and co-author of about 250 publications in international scientific journals, he is on the editorial boards of, and serves as an ad hoc reviewer for several international journals.
Professor Pantaleo is Professor of Medicine and Chief of the Division of Immunology and Allergy (IAL) and of the Laboratory of AIDS Immunopathogenesis at the Centre Hospitalier Universitaire Vaudois, University of Lausanne, Switzerland. Since 2007, he has also served as the Executive Director of the Swiss Vaccine Research Institute, and in 2009, he became a member of the WHO Vaccine Program scientific committee and a member of the science committee of the Global HIV Vaccine Enterprise.
Robert F. Siliciano and Janet Siliciano
In 1995, the Siliciano laboratory provided the first demonstration that latently infected CD4+ T cells were present in patients with HIV-1 infection. They went on to characterize this latent reservoir and to show that latently infected cells persist even in patients on prolonged antiretroviral therapy. The laboratory has gone on to characterize the different forms of HIV-1 that persist in patients on HAART and to explore potential strategies for eradicating the virus from this and other reservoirs.
Dr Robert F. Siliciano is a Professor of Medicine and Molecular Biology and Genetics at the Johns Hopkins University School of Medicine, USA and a member of the Howard Hughes Medical Institute, USA. Dr Siliciano did his undergraduate work at Princeton University, USA and then received his MD and PhD degrees from Johns Hopkins. After a postdoctoral fellowship at Harvard Medical School, USA, he joined the faculty at Johns Hopkins. He is the recipient of a Distinguished Clinical Scientist Award from the Doris Duke Charitable Foundation and two NIH Merit Awards. In 2002, he became an Investigator in the Howard Hughes Medical Institute. He is a past Chairman of the NIH AIDS and Related Research Study Section. He currently directs the MD-PhD program at Johns Hopkins.
Dr Janet Siliciano is an Assistant Professor of Medicine at Johns Hopkins. She did her undergraduate work at the University of New Hampshire, USA and received a PhD in Biochemistry from the Johns Hopkins University School of Medicine. After postdoctoral fellowships at Harvard Medical School and the Johns Hopkins University School of Medicine, she joined the faculty at Johns Hopkins in the Department of Medicine. Longitudinal studies by Dr Janet Siliciano demonstrated that because of the extraordinary stability of this reservoir, eradication of HIV-1 infection with antiretroviral therapy alone would never be possible, a finding which led to a fundamental change in the treatment strategy for HIV-1 infection. She also provided the first evidence that in infected individuals, latent HIV-1 genomes were integrated in active cellular genes, a finding which led to a revision in thinking about mechanisms of latency.